Tedizolid as step-down therapy following daptomycin versus continuation of daptomycin against enterococci and methicillin- And vancomycin-resistant Staphylococcus aureus in a rat endocarditis model

Kavindra Singh, Cesar A. Arias, Barbara E. Murray

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Tedizolid (TZD) and daptomycin (DAP) were assessed in a rat endocarditis model against Enterococcus faecalis, Enterococcus faecium (resistant to vancomycin and ampicillin), and Staphylococcus aureus. As a monotherapy, TZD for 5 days was not effective in a comparison with no-treatment controls, while DAP for 5 days was significantly effective against these bacteria. Step-down therapy (DAP for 3 days followed by TZD for 2 days) was as effective as DAP for 5 days and was comparable to 3 days of DAP plus ceftriaxone against all bacteria and to 3 days of DAP plus gentamicin against E. faecalis OG1RF.

Original languageEnglish (US)
Article numbere02303-19
JournalAntimicrobial Agents and Chemotherapy
Volume64
Issue number5
DOIs
StatePublished - May 1 2020

Keywords

  • Daptomycin
  • E. faecalis
  • E. faecium
  • Enterococci
  • Experimental endocarditis
  • MRSA/VRSA
  • Staphylococci
  • Tedizolid

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Tedizolid as step-down therapy following daptomycin versus continuation of daptomycin against enterococci and methicillin- And vancomycin-resistant Staphylococcus aureus in a rat endocarditis model'. Together they form a unique fingerprint.

Cite this